<DOC>
	<DOCNO>NCT02029482</DOCNO>
	<brief_summary>This single-center , randomize , double-blind , placebo-controlled , up-titration Phase 1 study . Sixteen subject two group ( least 40 % subject either male female sex ) , 12 subject active treatment group up-titration scheme 10 100 mg , 4 subject placebo treatment group . Subjects administer ascend dos ACT-128800/placebo daily 3 day dose level : 10 mg , 20 mg , 40 mg , 60 mg , 80 mg , 100 mg .</brief_summary>
	<brief_title>Study Investigate Safety , Tolerability , Pharmacokinetics , Pharmacodynamics ACT-128800 Healthy Subjects</brief_title>
	<detailed_description />
	<criteria>Signed informed consent local language prior studymandated procedure . Age 18 65 year ( inclusive ) screening . Body mass index ( BMI ) 18 30 kg/m^2 ( inclusive ) . Women childbearing potential require negative serum pregnancy test screen negative urine pregnancy test prior first drug intake agree use two method contraception screen visit 2 month study drug discontinuation . Systolic blood pressure 100150 mmHg , diastolic blood pressure 5090 mmHg measure leading arm , heart rate 5095 beat per minute ( inclusive ) measure electrocardiography ( ECG ) 5 minute supine position screening . ECG without clinically relevant abnormality screen . Hematology clinical chemistry result deviate normal range clinically relevant extent screening . Negative result urine drug screen screen . Ability communicate well investigator understand comply requirement study . ECG recording ; PQ/PR interval &gt; 200 m screening . Pregnant lactating woman . Known hypersensitivity excipients drug formulation . Known hypersensitivity beta2 adrenergic receptor agonist . Veins unsuitable intravenous puncture either arm ( e.g. , vein difficult locate , access puncture ; vein tendency rupture puncture ) . Treatment another investigational drug within 3 month prior screen . Excessive caffeine consumption , define ≥ 800 mg per day screening . History clinical evidence disease and/or existence surgical medical condition might interfere absorption , distribution , metabolism excretion study drug . Smoking within last month prior screen . Any immunosuppressive treatment within 6 week study drug administration . Previous treatment prescribe overthecounter medication ( include herbal medicine St John 's Wort ) within 2 week prior screen 5 halflives drug , whichever longer . Loss 250 mL blood within 3 month prior screen . Lymphopenia ( &lt; 1,000 cells/μL ) . Viral , fungal , bacterial protozoal infection within 4 week study drug administration ( e.g. , active herpes and/or cytomegalovirus infection ) . History clinical evidence suggestive active latent tuberculosis screening . Positive result hepatitis serology , except vaccinated subject , screen . Positive result human immunodeficiency virus serology screen . Forced expiratory volume 1 second ( FEV1 ) force vital capacity ( FVC ) &lt; 80 % predict value , FEV1/FVC ratio &lt; 0.7 screening . History asthma chronic obstructive pulmonary disease . Any cardiac condition illness ( include ECG abnormality ) potential increase cardiac risk subject standard 12lead ECG 24hour 3lead Holter ECG screen . History fainting , collapse , syncope , orthostatic hypotension , vasovagal reaction . Familial history sicksinus syndrome . History clinical evidence alcoholism drug abuse within 3year period prior screen . Alcohol abuse define regular weekly intake 21 unit . Legal incapacity limit legal capacity screen . Any circumstance condition , , opinion investigator , may affect subject 's full participation study compliance protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>ACT-128800</keyword>
</DOC>